systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-529Research ArticleСТАТЬИARTICLESСнижение сердечно-сосудистого риска: акцент на розувастатинMarkers of early target-organ brain damage in essential arterial hypertension: the search continues. Possibilities of diffusion tensor magnetic resonance imagingАникинГ. С.AnikinG. S.medi321@mail.ruСторожукИ. К.StorozhukI. K.noemail@neicon.ruФилязоваЯ. Ю.FilyazovaYa. Yu.noemail@neicon.ruФГБОУ ВО «Первый МГМУ им. И.М.Сеченова», ФГБУ «Поликлиника №3 УД Президента РФ»РоссияI.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation; Out-Patient Clinic №3 of Administration of the President of Russian FederationRussian FederationФГБУ «Поликлиника №3 УД Президента РФ»РоссияOut-Patient Clinic №3 of Administration of the President of Russian FederationRussian Federation2017231220221445054Copyright © Аникин Г.С., Сторожук И.К., Филязова Я.Ю., 20222022Аникин Г.С., Сторожук И.К., Филязова Я.Ю.Anikin G.S., Storozhuk I.K., Filyazova Y.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/529

Розувастатин является одним из часто назначаемых препаратов для первичной и вторичной профилактики инфаркта миокарда и инсульта. В статье рассмотрены основные исследования, подтверждающие эффективность розувастатина у пациентов с различным сердечно-сосудистым риском.

Rosuvastatin is one of the most frequently prescribed drugs for primary and secondary prevention of myocardial infarction and stroke. The present article deals with the main studies confirming the effectiveness of rosuvastatin in patients with different cardiovascular risks.

розувастатинпрофилактика сердечно-сосудистых осложненийгиперхолестеринемияатеросклерозrosuvastatinprevention of cardiovascular complicationshypercholesterolemiaatherosclerosisReferencesAgneta Å. et al. Low-Risk Diet and Lifestyle Habits in the Primary Prevention of Myocardial Infarction in Men. J Am Coll Cardiol 2014; 64 (13): 1299-306.Agneta Å. et al. Low-Risk Diet and Lifestyle Habits in the Primary Prevention of Myocardial Infarction in Men. J Am Coll Cardiol 2014; 64 (13): 1299-306.Chiuve S.E. et al. Primary prevention of stroke by healthy lifestyle. Circulation 2008; 118 (9): 947-54.Chiuve S.E. et al. Primary prevention of stroke by healthy lifestyle. Circulation 2008; 118 (9): 947-54.Boekholdt S.M, Hovingh G.K, Mora S. et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events. J Am Coll Cardiol 2014; 64 (5): 485-94.Boekholdt S.M, Hovingh G.K, Mora S. et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events. J Am Coll Cardiol 2014; 64 (5): 485-94.Jones P.H et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 2004; 26 (9): 1388-99.Jones P.H et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 2004; 26 (9): 1388-99.Ridker P, Danielson E, Fonseca F.A.H et al. for the JUPITER study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.Ridker P, Danielson E, Fonseca F.A.H et al. for the JUPITER study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.Грацианский Н.А. Сверхнизкий уровень холестерина липопротеинов низкой плотности в первичной профилактике у людей с повышенным С-реактивным белком. Результаты испытания JUPITER. Кардиология. 2009; 1: 73-5.Грацианский Н.А. Сверхнизкий уровень холестерина липопротеинов низкой плотности в первичной профилактике у людей с повышенным С-реактивным белком. Результаты испытания JUPITER. Кардиология. 2009; 1: 73-5.Crouse.JR 3rd, Raichlen J.S, Riley W.A. et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297 (12): 1344-53.Crouse.JR 3rd, Raichlen J.S, Riley W.A. et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297 (12): 1344-53.Nissen S.E, Nicolls S.J., Sapahi I. et al. ASTEROID Investigators. Effect of very high intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 296 (13): 1556-65.Nissen S.E, Nicolls S.J., Sapahi I. et al. ASTEROID Investigators. Effect of very high intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 296 (13): 1556-65.Rollefstad S, Ikdahl E, Hisdal J.et al. Rosuvastatin induced carotid plaque regression in patients with inflammatory joint diseases: the RORA-AS study. Arthritis Rheumatol 2015; 67: 1718-28.Rollefstad S, Ikdahl E, Hisdal J.et al. Rosuvastatin induced carotid plaque regression in patients with inflammatory joint diseases: the RORA-AS study. Arthritis Rheumatol 2015; 67: 1718-28.Ikdahl E, Hisdal J, Rollefstad S. et al. Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study. Arthritis Res Ther 2015; 17: 279.Ikdahl E, Hisdal J, Rollefstad S. et al. Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study. Arthritis Res Ther 2015; 17: 279.Kjekshus J, Apetre E, Barrias W et al. for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 1-14.Kjekshus J, Apetre E, Barrias W et al. for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 1-14.Karlson B.W. et al. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. Am J Cardiol 2016; 117 (9): 1444-8.Karlson B.W. et al. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. Am J Cardiol 2016; 117 (9): 1444-8.Тарловская Е.И., Нечаева Г.И., Мальчикова С.В., Семенкин А.А. Прогнозирование влияния оригинального и генерического розувастатина на прямые медицинские затраты при вторичной профилактике у пациентов с хроническими формами ишемической болезни сердца. Кардиоваск. терапия и профилактика. 2015; 14 (4): 29-37Тарловская Е.И., Нечаева Г.И., Мальчикова С.В., Семенкин А.А. Прогнозирование влияния оригинального и генерического розувастатина на прямые медицинские затраты при вторичной профилактике у пациентов с хроническими формами ишемической болезни сердца. Кардиоваск. терапия и профилактика. 2015; 14 (4): 29-37

The authors declare that there are no conflicts of interest present.